GENNARELLI, MASSIMO
 Distribuzione geografica
Continente #
NA - Nord America 16.279
EU - Europa 6.966
AS - Asia 5.170
SA - Sud America 85
AF - Africa 33
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 21
AN - Antartide 1
Totale 28.576
Nazione #
US - Stati Uniti d'America 16.196
CN - Cina 2.307
UA - Ucraina 1.934
SG - Singapore 1.262
PL - Polonia 1.076
HK - Hong Kong 1.005
IT - Italia 933
DE - Germania 890
FI - Finlandia 462
FR - Francia 433
GB - Regno Unito 398
IE - Irlanda 322
TR - Turchia 317
RU - Federazione Russa 297
IN - India 96
BR - Brasile 71
VN - Vietnam 69
CA - Canada 60
BE - Belgio 41
SE - Svezia 39
CZ - Repubblica Ceca 35
NL - Olanda 27
ID - Indonesia 25
AT - Austria 21
EU - Europa 21
AU - Australia 20
IR - Iran 16
ZA - Sudafrica 13
CH - Svizzera 12
MX - Messico 11
SA - Arabia Saudita 10
KR - Corea 8
MA - Marocco 7
MU - Mauritius 7
ES - Italia 6
KG - Kirghizistan 6
LT - Lituania 6
PA - Panama 6
RO - Romania 6
BG - Bulgaria 5
EG - Egitto 5
IL - Israele 5
JP - Giappone 5
AE - Emirati Arabi Uniti 4
EC - Ecuador 4
KZ - Kazakistan 4
LU - Lussemburgo 4
NO - Norvegia 4
PK - Pakistan 4
AZ - Azerbaigian 3
BD - Bangladesh 3
CL - Cile 3
HN - Honduras 3
HU - Ungheria 3
JO - Giordania 3
LA - Repubblica Popolare Democratica del Laos 3
LK - Sri Lanka 3
PH - Filippine 3
PT - Portogallo 3
AM - Armenia 2
AR - Argentina 2
BO - Bolivia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
PE - Perù 2
AL - Albania 1
EE - Estonia 1
GR - Grecia 1
GS - Georgia del Sud e Isole Sandwich Australi 1
IM - Isola di Man 1
IQ - Iraq 1
KW - Kuwait 1
LV - Lettonia 1
MK - Macedonia 1
MY - Malesia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
OM - Oman 1
RS - Serbia 1
TH - Thailandia 1
TN - Tunisia 1
TW - Taiwan 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 28.576
Città #
Fairfield 2.491
Woodbridge 1.991
Jacksonville 1.428
Houston 1.264
Ashburn 1.133
Ann Arbor 1.076
Warsaw 1.074
Cambridge 1.007
Hong Kong 1.000
Seattle 922
Singapore 867
Wilmington 826
Chandler 654
Princeton 602
Nanjing 516
Dublin 318
Beijing 291
Brescia 285
Istanbul 280
New York 246
Dearborn 230
Helsinki 216
Nanchang 210
Des Moines 204
Shenyang 153
Hebei 139
San Diego 131
Changsha 126
Moscow 122
Milan 101
Lancaster 100
Jinan 99
Shanghai 97
Jiaxing 84
Tianjin 84
Los Angeles 74
Dong Ket 68
Kunming 63
Verona 60
Norwalk 57
Boardman 54
Munich 54
The Dalles 54
Hangzhou 53
Zhengzhou 49
Lanzhou 48
Ningbo 47
London 45
Brussels 40
Haikou 39
Nuremberg 36
Romola 34
San Mateo 34
Toronto 34
Bolzano 32
San Francisco 30
Leawood 27
Brno 26
Guangzhou 26
Jakarta 24
Kocaeli 24
Washington 22
Fuzhou 21
Augusta 19
Chicago 19
Hefei 19
Changchun 18
Orange 17
Taizhou 17
Kilburn 16
Rome 15
Ardabil 14
Frankfurt am Main 13
Naples 13
Salt Lake City 13
Düsseldorf 12
Taiyuan 12
Vienna 10
Chiswick 9
Hounslow 9
Mexico City 9
Buffalo 8
Falkenstein 8
Lappeenranta 8
Phoenix 8
Québec 8
Salò 8
San Donà Di Piave 8
Redwood City 7
Basel 6
Bela-Bela 6
Bishkek 6
Cagliari 6
Canberra 6
Guastalla 6
Lauterbourg 6
New Bedfont 6
Ottawa 6
Casalmaggiore 5
Chengdu 5
Totale 21.923
Nome #
New Copy Number Variations in Schizophrenia 272
Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling 270
Exome sequencing in schizophrenic patients with high levels of homozygosity identifies novel and extremely rare mutations in the GABA/glutamatergic pathways 269
The effect of childhood trauma on blood transcriptome expression in major depressive disorder 228
Compound heterozygosity for a large CNV deletion and a rare missense mutation in the FSTL5 gene of a patient affected by schizophrenia. 226
Mutation within TARDBP leads to Frontotemporal Dementia without motor neuron disease. 208
Compound heterozygosity for a hemizygous rare missense variant (rs141999351) and a large CNV deletion affecting the FSTL5 gene in a patient with schizophrenia 183
Genome-wide analysis of consistently RNA edited sites in human blood reveals interactions with mRNA processing genes and suggests correlations with cell types and biological variables 181
The impairment of GABAergic pathway as one of the driver forces in the etiopathogenesis of schizophrenia: evidence from functional studies and gene-set enrichment analyses 177
New biological pathways for major depression: gene expression decomposition in G x E components 168
Altered gene expression in schizophrenia: findings from transcriptional signatures in fibroblasts and blood 167
Insulin-like Growth Factor 1 Differentially Affects Lithium Sensitivity of Lymphoblastoid Cell Lines from Lithium Responder and Non-responder Bipolar Disorder Patients 167
Reduced function of the serotonin transporter is associated with decreased expression of BDNF in rodents as well as in humans. 166
Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons 161
Copy number variants in attention-deficit hyperactive disorder: identification of the 15q13 deletion and its functional role. 160
Genomic restricted maximum likelihood (GREML) analysis to estimate the heritability of response/resistance in major depressive disorder (MDD) 159
Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients. 154
Acute Footshock Stress Induces Time-Dependent Modifications of AMPA/NMDA Protein Expression and AMPA Phosphorylation 153
Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. 152
The role of the potassium channel gene KCNK2 in major depressive disorder 152
Association between baseline serum vascular endothelial growth factor levels and response to electroconvulsive therapy. 144
-G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: Meta-analysis plus association study 144
A novel homozygous mutation in GAD1 gene described in a schizophrenic patient impairs activity and dimerization of GAD67 enzyme 144
TARDBP mutations in frontotemporal lobar degeneration: frequency, clinical features, and disease course. 143
Gene per la neuregulina 1 e schizofrenia: ulteriori evidenze di associazione 139
Proteasome system dysregulation and treatment resistance mechanisms in major depressive disorder 137
The MCP-1 gene (SCYA2) and mood disorders: preliminary results of a case-control association study. 136
Insulin-like growth factor binding protein 2 in bipolar disorder: An expression study in peripheral tissues 136
Next Generation Sequencing Analysis in Early Onset Dementia Patients 131
The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis 130
Acute Stress Responsiveness of the Neurotrophin BDNF in the Rat Hippocampus is Modulated by Chronic Treatment with the Antidepressant Duloxetine. 129
Association study and mutational screening of SYNGR1 as a candidate susceptibility gene for schizophrenia 129
5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression 128
A genome-wide investigation of SNPs and CNVs in schizophrenia. 127
MTHFR: Genetic variants, expression analysis and COMT interaction in major depressive disorder 127
Supporting evidence for using biomarkers in the diagnosis of MCI due to AD 127
3' UTR (AGG)n repeat of glial cell line-derived neurotrophic factor (GDNF) gene polymorphism in schizophrenia. 126
The Expression of VGF is Reduced in Leukocytes of Depressed Patients and it is Restored by Effective Antidepressant Treatment 125
Glucose metabolism alterations in patients with bipolar disorder 124
-G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: Meta-analysis plus association study 122
Atypical presentation of a novel Presenilin 1 R377W mutation: sporadic, late-onset Alzheimer disease with epilepsy and frontotemporal atrophy. 121
Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study: Differentiating between Baseline 'Predictors' and Longitudinal 'Targets' 121
Serum leptin levels are higher in females affected by frontotemporal lobar degeneration than Alzheimer's disease 120
BDNF serum levels, but not BDNF Val66Met genotype, are correlated with personality traits in healthy subjects. 120
The Role of allelic variants of FK506-binding protein 51 (FKBP5) gene in the development of anxiety disorders 120
Role of allelic variants of FK506-binding protein 51 (FKBP5) gene in the development of anxiety disorders. 120
Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. 119
BDNF Val66Met polymorphism and protein levels in amniotic fluid. 119
ErbB3 mRNA leukocyte levels as a biomarker for major depressive disorder. 118
The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia 118
Peripheral whole blood microRNA alterations in major depression and bipolar disorder 118
A putative regulatory subunit (NR3A) of the NMDA receptor complex as candidate gene for susceptibility to schizophrenia: a case-control study. 118
STUDY OF THE EFFECTS ON DNA OF ELECTROMAGNETIC FIELDS USING CLAMPED HOMOGENEOUS ELECTRIC FIELD GEL ELECTROPHORESIS. 117
The role of GRIK4 gene in treatment-resistant depression 117
A genome-wide pharmacogenomic study of patients with schizophrenia suggests that GRM7 mediates the effects of risperidone on positive symptoms 116
Possible Influence of a Non-Synonymous Polymorphism Located in the NGF Precursor on Susceptibility to Late-Onset Alzheimer's Disease and Mild Cognitive Impairment. 116
TWO PEDIGREES OF AUTOSOMAL DOMINANT ATRIOVENTRICULAR CANAL DEFECT (AVCD): EXCLUSION FROM THE CRITICAL REGION ON 8p. 115
Schizophrenia susceptibility and NMDA-receptor mediated signalling: an association study involving 32 tagSNPs of DAO, DAOA, PPP3CC, and DTNBP1 genes. 115
Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders. 115
Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein. 114
VEGF Haplotypes are Associated with Increased Risk to Progressive Supranuclear Palsy and Corticobasal Syndrome. 112
Glucocorticoid-related molecular signaling pathways regulating hippocampal neurogenesis. 112
Seizure Adequacy Markers and the Prediction of Electroconvulsive Therapy Response 112
Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series 112
Functional study of a novel homozygous mutation in the GAD1 gene, detected in a patient with schizophrenia. 112
BDNF Genotype and Baseline Serum Levels in Relation to Electroconvulsive Therapy Effectiveness in Treatment-Resistant Depressed Patients 112
Alterations of Brain-Derived Neurotrophic Factor Serum Levels in Patients with Alcohol Dependence. 111
Serum sortilin-derived propeptides concentrations are decreased in major depressive disorder patients 111
CTG repeats distribution and Alu insertion polymorphism at myotonic dystrophy (DM) gene in Amhara and Oromo populations of Ethiopia 110
Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels 110
Study of the in vitro modulation exerted by the antidepressant drug escitalopram on the expression of candidate microRNAs and their target genes 110
Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates 110
Polymorphic CA repeat in IGF-I gene: lack of association with schizophrenia. 109
Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: Comparison with methylphenidate. 109
INFLAMMATORY AND NEUROTROPHIC FACTORS UNBALANCE IN LEUKOCYTES OF FIRST EPISODE PSYCHOSIS PATIENTS 109
Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis. 109
Derivation of midbrain dopaminergic neurons from human inducible pluripotent stem cells to model neurological disorders. 108
GENOTYPING OF SPINAL MUSCULAR ATROPHY FAMILIES WITH LINKED DNA PROBES. 108
The influence of psychiatric screening in healthy populations selection: a new study and meta-analysis of functional 5-HTTLPR and rs25531 polymorphisms and anxiety-related personality traits. 108
Molecular signature of disease onset in granulin mutation carriers: a gene expression analysis study. 108
Understanding phenotype variability in frontotemporal lobar degeneration due to granulin mutation. 108
Heterozygous TREM2 mutations in frontotemporal dementia 108
An association of GRIK3 Ser310Ala functional polymorphism with personality traits. 107
Variations in the NMDA receptor subunit 2B gene (GRIN2B) and schizophrenia: a case-control study. 107
Long-Term duloxetine treatment normalizes altered brain-derived neurotrophic factor expression in serotonin transporter knockout rats through the modulation of specific neurotrophin isoforms. 107
Immune and metabolic alterations in first episode psychosis (FEP) patients 107
Prediction of myotonic dystrophy clinical severity based on the number of intragenic [CTG]n trinucleotide repeats. 106
Clinical and medial temporal features in a family with mood disorders. 106
Influence of GRIK4 genetic variants on the electroconvulsive therapy response 106
α-Synuclein and Glia in Parkinson’s Disease: A Beneficial or a Detrimental Duet for the Endo-Lysosomal System? 106
MEIOTIC DRIVE AT THE MYOTONIC DYSTROPHY LOCUS. 105
A single polymerase chain reaction-based protocol for detecting normal and expanded alleles in myotonic dystrophy. 105
Antidepressant treatments change 5-HT2C receptor mRNA expression in rat prefrontal/frontal cortex and hippocampus 105
Analysis of Copy Number Variations in Schizophrenia Italian Patients 104
Genetic variations and association. 104
Genetic Variation in the G720/G30 Gene Locus (DAOA) Influences the Occurrence of Psychotic Symptoms in Patients with Alzheimer's Disease. 104
Unraveling epigenomic signatures and effectiveness of electroconvulsive therapy in treatment-resistant depression patients: a prospective longitudinal study 103
EXPANSION OF THE MYOTONIC DYSTROPHY GENE IN ITALIAN AND SPANISH PATIENTS 103
Association between -G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. 103
Vascular Endothelial Growth Factor (VEGF) serum concentration during electroconvulsive therapy (ECT) in treatment resistant depressed patients. 103
Totale 13.087
Categoria #
all - tutte 154.899
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 154.899


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.859 0 0 0 0 0 0 0 0 0 902 530 427
2020/20214.626 105 495 186 537 220 500 213 513 683 414 550 210
2021/20222.396 158 541 56 56 14 98 206 142 172 238 206 509
2022/20232.084 349 12 31 146 190 620 6 208 315 32 94 81
2023/20242.135 127 52 188 131 95 349 60 72 588 37 37 399
2024/20253.358 47 55 82 615 592 516 392 189 513 357 0 0
Totale 29.088